Stockreport

Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma, Inc.  (LYEL) 
PDF SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company advancing a diver [Read more]